Teniposide Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50 mg/10 mL (5 mg/mL)
Reference Brands: Vumon.(US & EU)
Category:
Oncology Cancer Care
Teniposide Injection (Vumon) is an oncology drug used to treat acute lymphoblastic leukemia (ALL) and neuroblastoma. Available in the U.S. and EU, it is supplied as 50 mg/10 mL (5 mg/mL) for intravenous infusion. Teniposide works by inhibiting topoisomerase II, preventing cancer cell division. Administered in hospital settings, it is part of chemotherapy regimens and requires careful handling due to potential side effects.
Teniposide Injection is available in Injection
and strengths such as 50 mg/10 mL (5 mg/mL).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Teniposide Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Teniposide Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Teniposide Injection (Vumon) is a chemotherapy drug used in the treatment of acute lymphoblastic leukemia (ALL) and neuroblastoma. Available in the U.S. and EU, Teniposide is typically supplied as 50 mg/10 mL (5 mg/mL) for intravenous infusion. As a topoisomerase II inhibitor, it interferes with DNA replication in cancer cells, preventing their division. This injectable formulation is essential in multi-drug chemotherapy regimens and is administered under the supervision of healthcare professionals in clinical settings. It requires careful handling due to potential side effects, including bone marrow suppression and liver toxicity, making it suitable for B2B pharmaceutical distribution in oncology.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing